Effects of Allosteric Mutations on Dihydrofolate Reductase by Okondo, Marian
Montclair State University 
Montclair State University Digital Commons 
Theses, Dissertations and Culminating Projects 
8-2015 
Effects of Allosteric Mutations on Dihydrofolate Reductase 
Marian Okondo 
Follow this and additional works at: https://digitalcommons.montclair.edu/etd 
 Part of the Chemistry Commons 
MONTCLAIR STATE UNIVERSITY
A Master’s Thesis Submitted to the Faculty of 
Montclair State University
In Partial Fulfillment of the Requirements 
For the Degree of 
Master of Science Chemistry 
August 2015
J  Effects of Allosteric Mutations on Dihydrofolate Reducías^
By
Marian Okondo
College Science and Mathematics Thesis Committee:
Department Chemistry
Thesis Sponsor: Dr. Nina Goodey
Committee Member: Dr. Jim Dyer
Committee Member Dr. David Konas
ABSTRACT
Dihydrofolate reductase (DHFR) is an essential enzyme necessary in the synthesis of 
DNA precursors. DHFR acquires resistance to numerous known anti-folates and this has 
led to the continuous need to discover novel and selective DHFR inhibitors. Allosteric 
mutations on Bacillus stearothermophilus (Bs.) DHFR were previously found to alter 
inhibitor binding and specificity. In this work, we investigate how these mutations affect 
the conformational motions of DHFR associated with inhibitor binding. Two distal 
allosteric mutations, isoleucine at position 86 to alanine (I86A) and tyrosine at position 
127 to alanine (Y127A) were separately introduced to C73A/S131C, a previously 
modified wild type DHFR to give C73A/I86A/S131C and C73A/Y127A/S131C DHFRs. 
The modified C73A/S131C DHFR contains a site for attachment of fluorescent label, N- 
[2-(l-maleimidyl) ethyl]-7-(diethyl amino) coumarin-3-carboxamide (MDCC).
Development of C73A/S131Cmdcc DHFR allowed for a method to study two native 
conformations of DHFR that could otherwise not be studied by intrinsic fluorescence 
alone. Stopped-flow instrumentation together with fluorescence is used to study the 
kinetics of protein structural motions. This approach allowed us to examine the 
conformational changes associated with methotrexate (MTX) and pyrimethamine (PYR) 
binding, for the mutants and compare them to C73A/S131C DHFR. Intrinsic tryptophan 
fluorescence of the three DHFR constructs (C73A/S131C, 186A, Y127A) revealed a 
different conformational change upon PYR binding to one conformer compared to MTX 
binding. To study the second conformer, MDCC is covalently attached to the cysteine at 
position 131 on the DHFR (C73A/S131Cmdcc» I86Amdcc? Y127Amdcc) and all three 
enzymes show a conformational change, different from that observed by intrinsic 
fluorescence upon inhibitor binding that are inhibitor specific. This study provides insight 
on the conformational changes associated with inhibitor binding. How the conformational 
changes are inhibitor specific. As well as how the mutants’ (I86A and Y127A) affect the 
conformational changes compared to C73A/S131C. Understanding what happens during 
inhibitor binding and the role of allosteric mutations on ligand binding specificity can 
inform design and repurposing of selective DHFR drug compounds.
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ABBREVIATIONS
DHFR: Dihydrofolate Reductase Enzyme 
Bs. DHFR: Bacillus stearothermophillus DHFR 
WT: Wild type Bs. DHFR
MDCC:N-[2-( 1 -maleimidyl)ethyl]-7-(diethylamino)coumarin-3-carboxamide fluorescent 
tag
C73A/S131C DHFR: Modified WT DHFR 
C73A/S131Cmdcc DHFR: MDCC labeled C73A/S131C DHFR
I86A: DHFR construct with Isoleucine replaced at position 86 with Alanine on 
C73A/S131C
I86AMdcc: MDCC labeled I86A DHFR
Y86A: DHFR construct with Tyrosine replaced at position 127 with Alanine on 
C73A/S131C
Y127Amdcc: MDCC labeled Y127A DHFR 
DHF: 7,8-dihydrofolate 
THF: 5,6,7,8- tetrahydrofolate
Allosteric Mutations: Mutations not located in the active site of DHFR but affect enzyme 
function
LB: Luria Bertani
Ampioomg/mL* Ampicillin at a concentration of lOOmg/mL 
diH20: Distilled Water
IPTG: isopropyl-|3-D-thiogalactopyranoside for inducing expression 
HEPES: N-2-hydroxyethylpiperazine-N-2-ethanelsufonic acid 
NaCl: Sodium Chloride
DTT: Dithiothreitol
MTX: Methotrexate
PYR: Pyrimathemine
kcat: The number of substrate molecules each substrate site converts to a product per unit 
time
Kj: The Inhibitor concentration needed to produce half maximum inhibition
E: A conformer of Bs. DHFR
E’: Another conformer of Bs. DHFR
ki and k_i : Association and Dissociation rate of E
k4 and k.4 : Association and Dissociation rate of E’
k2 and k.2 : Conformational change rates
MTEN buffer : (50mM 2-(N-morpholino) ethanesulfonic acid, 25mM tris
(hydroxymethyl)-aminomethane, 25mM ethanolamine and lOOmM NaCl) at pH 7
Introduction
Dihydrofolate reductase (DHFR) is a ubiquitous enzyme, which catalyzes the reduction 
of 7,8-dihydrofolate (DHF) to 5,6,7,8- tetrahydrofolate (THF), an essential molecule used 
for the synthesis of important metabolites including DNA precursors7. For this reason, 
DHFR is a well-established drug target for the treatment of cancers and some infectious 
diseases 2 7 4. However, DHFR acquires resistance to a number of known inhibitors such 
as methotrexate (anticancer), pyrimithamine (protozoan infections) and trimethoprim 
(antibacterial) to mention a few 5. Amino acid residue mutations at highly conserved 
positions on DHFR are thought to be responsible for the resistance 6 7. Understanding the 
role these residues play in inhibitor binding, catalysis and specificity is important in the 
rationale of drug design.
Enzymes exhibit flexibility and conformational changes upon ligand binding and 
catalysis. A “network” of amino acid residues in and away from the active site may 
allosterically regulate and form the “global protein dynamics” that play a role in enzyme 
catalysis 10. In this context, global protein dynamics refers to the overall motions 
exhibited by all the atoms present in DHFR. DHFR is one of the most studied enzymes 
for enzyme flexibility u '13 and it is known that the active site residues are involved in 
ligand binding 14 Still, an extensive number of experimental, computational and 
theoretical studies, have provided evidence to show, besides active site residues, coupled 
motions of residues proximal and distal from the active site play a role in ligand binding 
and catalysis. 77'7‘715'20
In published work 6, using a computational method, Goodey and co-workers were 
able to predict residues within and away from the active site that not only affected
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enzyme catalysis but were also found to be involved in inhibitor specificity. To validate 
the distal residues predicted, determinant regions on Bacillus stearothermophilus (Bs) 
DHFR were identified; allosteric mutations were introduced and found to affect inhibitor 
binding and specificity 21.
In this work, we try to understand the effect of these allosteric mutations on 
ligand binding and specificity by studying the overall motions of Bs. DHFR containing 
single allosteric mutations and comparing them to the wild type. We introduce two distal 
allosteric mutations; these mutations are similar to those introduced in the determinant 
region study2/ , isoleucine in position 86 to alanine (I86A) and tyrosine in position 127 to 
alanine (Y127A), separately, to a modified Bs. DHFR (C73A/S131C DHFR) to give 
C73A/I86A/S131C and C73A/Y127A/S131 Ca .
The C73A/S131C DHFR was previously modified to develop a novel method for 
studying temperature dependent conformational changes associated with inhibitor 
binding using stopped flow instrumentation together with intrinsic tryptophan 
fluorescence and extrinsic fluorescence. The introduction of a cysteine at position 131 
provided a specific site for covalent attachment of the fluorescent label N-[2-( 1 - 
maleimidyl)ethyl]-7-(diethylamino)coumarin-3-carboxamide (MDCC). MDCC does not 
respond to the absence or presence of an inhibitor, rather to the conformational motions 
in its environment that cannot be detected by intrinsic tryptophan fluorescence alone 22.
This method allowed us to study the conformational motions of the mutants 
during methotrexate (MTX) and pyrimethamine (PYR) binding and compare them to 
C73A/S131C. Here, we report on the mechanism of binding of PYR to DHFR as well as
a C73A/I86A/ S 131C and C73A/Y 127A/S 131C will be referred to as I86A and Y 127A 
respectively
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the conformational changes associated with PYR binding a study that has not been done 
before.
Some of the questions we try to answer are as follows: 1) Do the allosteric 
mutations affect the conformational motions associated with inhibitor binding? 2) Are the 
conformation motions, inhibitor specific? 3) Do the allosteric mutations change the 
conformational equilibrium of DHFR prior to inhibitor binding and what is the 
significance of these effects on inhibitor binding and specificity?
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Materials and Methods
1. Construction of I86A mutant gene
1.1 QuickChange Mutagenesis
I86A mutation was introduced to modified C73A/S131C Dihydrofolate reductase 
enzyme (DHFR) DNA"(DNA was from Sarah Cho, a student in Dr. Goodey’s Lab) by
mutagenesis, using the QuickChange II Site-Directed Mutagenesis kit. (Table 1)
Volume Solution
lOpL 5X reaction buffer
0.26pL (lOng) C73A/S131C DHFR DNA
2.5pL I86A 5’GGAAGTCAAGCAATGGGCCGCATCG (forward Primer)
2.5pL 186A 5 ’ GCGATGCGCCCATTGCTTGACTTCC (reverse primer)
lpL dNTP mix
33.74pL Double Distilled (dd) H2O
Table 1: Protocol for the sample reactions to perform QuickChange II Site-Directed 
Mutagenesis for the introduction of I86A to C73A/S131C DHFR.
Three PCR sample reaction mixtures were made and 0.5pL of Pfu turbo DNA 
polymerase was added. For the control reaction, no DNA was added. The samples and 
control were placed in the thermo-cycler (Fig 1) and left overnight after the reaction was 
over. Reaction parameters are included in (Table 2) and were based on recommendations 
suggested in the QuickChange II Site- directed Mutagenesis protocol 2/?for optimal 
results.
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Figure 1: A picture of the thermo cycler used for the PCR mutagenesis reaction. 
Eppendorf Mastercycler gradient thermo cycler using round top PCR tubes setting 
was used.
Cycles Temperature Time
1 98°C 30s
22 98°C 10s
60°C 30s
72°C 3 min
Store 4°C Overnight
Table 2: QuickChange II Site Directed Mutagenesis cycling parameter methods for 
introducing I86A mutation to C73A/S131C DHFR.
Dpnl digestion was performed the next day, by adding lpL of Dpnl restriction 
enzyme (10 U/pL) directly to each reaction and incubated for 1 h at 37° C.
1.2 Transformation of Digestion reaction in XLBlue Super Competent Cells 
To lOOpL of XLBlue cells super competent cells (made competent by Sarah Cho), 
1 pL of the digestion reaction was directly added and the reaction mixture placed on ice 
for 30 min. The cells were heat shocked for 2 min at 42 °C and placed on ice for 2min. 
Luria Bertani (LB) broth (900pL) was added and the cells were incubated for 45 min at
5
37 °C. The cells were pipetted on an LBampioo(mg/mL) plate and spread using a sterile loop. 
The plates were incubated overnight at 37 °C. The same procedure was done for the 
control reaction, excluding the addition of lpL of the digestion reaction.
1.3 DNA Plasmid Preparation/Purification using QIAprep Spin Miniprep Kit
Colonies were collected from the incubated plates (Fig.2) and a 7 mL LB + 7pL 
Ampicillinioomg/mL(Ampioomg/mi) overnight culture was grown in the shaker at 37°C. The 
next day, a 1:1 1 mL 50% glycerol stock of the cells was made from the overnight 
culture.
Figure 2: Plate containing colonies collected for DNA plasmid preparation and 
purification using the QIA prep spin Miniprep kit.
The cells were harvested by centrifuging the overnight culture in three, 1.5 mL 
micro-centrifuge tubes at 13,000 rpm on a tabletop centrifuge (fig.3). The supernatant 
was poured out and an additional 1.5mL of the overnight culture was added to the tubes 
and centrifuged at the same settings.
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Figure 3: Eppendorf tabletop centrifuge, model 5418, that was used in the 
purification of DNA plasmid colonies using the QIA prep spin Miniprep kit 
collected from transformation LB agar plates containing lOOmg/ml ampicillin.
Using a QIAprep Miniprep kit protocol24, the pellets in the three 1.5mL 
microcentrifuge tubes were separately suspended in 250pL Buffer PI (containing 
RNAse) 250 pL Buffer P2, 350 pL Buffer N3 and centrifuged for lOmin at 13,000 rpm. 
The supernatant from all three tubes were added gradually to the spin column and 
centrifuged for 30s at 13,000 rpm until all the supernatant was added to the column. The 
column was washed with 0.5mL Buffer PB and 0.75mL Buffer PE (containing 20mL 
100% Ethanol) each time centrifuging for 30s at 13,000rpm. The column was centrifuged 
for 2min at 13,000rpm to remove the excess ethanol from Buffer PE. Finally, 30pL 
diPLO was added to the column, which was incubated for 5min and centrifuged for 1 min 
at 13,000rpm.
7
To determine the concentration of the eluted DNA, 2pL of the protein was placed 
directly onto the optical measurement surface of a Thermo Scientific™ NanoDrop 2000c 
UV-Vis spectrophotometer using d i^ O  as a blank at the DNA module setting at 260nm 
wavelength.
Once the concentration was determined, to confirm the mutation, lOpL of the 
purified DNA plasmids were sent for sequencing (done by Adam Parker of the Molecular 
Biology department) and the amino acid sequence alignments were done using Biology 
Workbench. (Refer to results section 2)
1.4 Transformation of 186A construct into BL21 Escherichia coli (Ec) 
Expression Cells
The XLBlue cells transformation protocol, described in materials and methods 
section 1.2 was used. To lOOpL of competent BL21 Ec. cells, lpL of purified I86A 
DHFR plasmid DNA was directly added, to the transformation reaction. No plasmid was 
added to the Ec. cells for the control reaction.
2. Protein Expression, Purification and Preparation of MDCC Labeled DHFR
2.1 Protein Expression DHFR in BL21 Ec. Cells
BL21 C73A/S131C DHFR from a glycerol stock was added to two culture tubes 
containing 5mL LB broth+ 5uL Arnpioomg/mi- The cells were grown overnight and 2.5mL 
were added to 4 flasks containing 250mL LB + 250pL Arnpioomg/mi at 37°C. At an OD600 
of 0.6, the cells were induced with 50pL of 1M isopropyl-p-D-thiogalactopyranoside 
(IPTG) to give a final concentration of 0.2mM and grown for 18h at 30°C and 225rpm. 
The cells were centrifuged at 5000rpm for 15min at 4°C in a Beckman Coulter Avanti J-
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265 XP centrifuge using the JA-17 rotor and washed with 200ml 0.9% Sodium Chloride 
(NaCl) and centrifuged again as above. The pellets were stored at -80°C. A similar 
protocol was used for the purification of I86A and Y127A (50% glycerol stock of Y127A 
was given by Sarah Cho).
2.2 Protein Purification ofDHFR
The pellets were suspended in 40mM N-2-hydroxyethylpiperazine-N-2- 
ethanelsufonic acid (HEPES) buffer at pH6.8 and lysed by sonication for 5min at setting 
5, 10% duty cycle on ice and centrifuged at 17,000rpm for 20min. The supernatant was 
loaded onto an equilibrated SP-Sepharose C-25 column; saving 80pL and collecting 80pl 
of the flow through, The column was washed with 25 ml of HEPES and the protein was 
eluted with 0.2M NaCl, 40mM HEPES, ImM DTT, 10 % glycerol (pH 6.8). Presence of 
protein in each fraction was confirmed using 5X Biorad Bradford assay (80pL Bradford 
solution +20pL sample)(fig 4).
Figure 4:A. Columns containing SP-Sepharose C-25 resin that the lysate was loaded 
onto. B. Bradford protein assay (80pL Bradford solution +20pL sample) done in a 
96 well plate. Blue indicates presence of protein while brown shows no protein 
present.
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The protein was concentrated and washed with 40mM HEPES, ImM DTT and 
10% glycerol in a swing bucket rotor in an Eppendorf tabletop Centrifuge, model 581 OR 
at 3x20min at 4000rpm. The concentration of the protein was calculated using beer law 
equation (eq. 1) by determining the absorbance at 280nm from the Thermo Scientific™ 
NanoDrop 2000c on UV-Vis setting and an extinction coefficient of 25565 M 'em ', 
1.386mg'cm'. Typical final concentration and volume of protein obtained from a 
500mL pellet of protein is 1.5mL of 31 pM and 0.58 mg/mL at an absorbance of ~ 0.08 at 
280nm wavelength. Giving a typical yield 0.88mg per 500mL.
C in mg/ml: e — 1.368mLmg 'em 
C in M: £= 22565 
l = 0.1cm
Equation 1: Beers law equation used to calculate protein concentration of purified 
C73A/S131C DHFR.
An SDS-PAGE electrophoresis was done at 145V for 45min (lOpL of 4X SDS 
loading dye +30pL sample) to view the size of the protein and its % purity (Fig 5). The 
same protocol was used for I86A and Y127A constructs.
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Figure 5: SDS-PAGE apparatus with lanes loaded with ladder and samples collected 
through out purification process.
2.3 Preparation of C73A/S131 Cmdcc, I86Amdcc and Y127Amdcc DHFR
To covalently attach the fluorescent label to C73A/S131C DHFR, the enzyme was 
washed in pH 7.2 40mM HEPES to remove excess DTT and exchange the buffer. A 4- 
fold molar excess of 0.22mM stock solution of MDCC fluorophore (MW 383.4 g/mol), 
dissolved in dimethyl sulfoxide (DMSO), was added drop-wise to the purified 
C73A/S131C DHFR in pH 7.2 HEPES buffer. The final concentrations were 128pM of 
MDCC and 32pM and enzyme respectively.
The mixture was covered with aluminum foil to protect the sample from light and 
incubated at room temperature for 2 h. The sample was dialyzed twice, once overnight 
and 4h the next day at 4 °C in at least 200X 40mMHEPES, pH 6.8 to remove excess dye 
and to exchange buffer. A similar procedure was used to attach MDCC to I86A and 
Y127A with varying incubation times, I86A (3h), Y127A (5 h shaking).
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2.4 Calculation o f %Labeling efficiency ofMDCC attachment to DHFR
The extinction coefficient of DHFR (25,565 M-lcm-1 at 280 nm) and of MDCC 
(10,000 M-lcm-1 at 280 nm and 50,000 M-lcm-1 at 419 nm) were used to calculate 
labeling efficiency). Labeling efficiency was found to be ~87 % from absorbance 
measurements at 280 and 419 nm using a Thermo Scientific NanoDrop 2000c UV-Vis 
spectrophotometer for C73A/S131Cmdcc and I86Amdcc- A labeling efficiency of 40% 
was obtained for Y127AMdcc-
STEP 1: Determining the concentration of MDCC present at 419nm 
MDCC concentration is calculated using beers law and absorbance obtained at 419nm
Labeling Efficiency  
A4,9„m = 0.017
e= 50,000M~lcm~l,l  = 0.\cm  
~ 0.017M 10V M  . „ w
50,000M _1cra~ x 0.1 cm \M
STEP 2: Calculating absorbance contributed by MDCC at 280nm 
A 280 nm contributed by MDCC
A = 3.4uM x 0 .1cm x 10,000M x . = 0.0034
l06pM
STEP 3: Determining the concentration of Enzyme present in solution 
The enzyme absorbance at 280nm is calculated by subtracting the MDCC absorbance at 
280nm from the overall 280nm absorbance.
Enzyme A 280nm— Overall A 280nm " MDCC A 280nm 
0.075- 0.0034 = 0.0716
Enzyme Concentration
c=  0.01X6 M x 1 0 V M ,28 o ,/;M
25565cm x 0.1cm 1M
STEP 4: Calculating % Labeling Efficiency
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To obtain the % labeling efficiency, the ratio of the concentration of the label to enzyme 
is calculated.
Labeling efficiency
MDCC Concentration------------------------------x 100%
Enzyme Concnetration
3,4't<M X100% =12.1%
28.01 juM
3. Kinetic Analysis of Inhibitor binding to DHFR enzymes using Stopped Flow 
Instrumentation
3.1 Determination of Inhibitor Binding Kinetics to C73A/S131C DHFR
To determine the conformational motions associated with binding and after 
binding using stopped-flow instrumentation together with intrinsic fluorescence, 2pM of 
C73A/S131C DHFR was mixed with 2-200pM of an inhibitor15 in MTEN buffer (50mM 
2-(N-morpholino) ethanesulfonic acid, 25mM tris (hydroxymethyl)-aminomethane, 
25mM ethanolamine and lOOmM NaCl) at pH 7, 25°C in an applied photo physics SX20 
Stopped-flow kinetics instrument with 1mm slit width. (Figure 6) giving a final 
concentration of, lpM of C73A/S131C DHFR was mixed with l-100pM of an inhibitor. 
The technical specification settings for the stopped flow instrumentation can be found in 
Appendix II 25.
b Inhibitor refers to MTX and PYR
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Syringe B
Syringe A
Sequential Mix Dnve Ram 
Single Mix D ine  Ram
Optical Cell Homing
Auto Stop Assembly (Top)
Stop V live
Reservoir Syringes
Dnve Valve Controls
Water Bath Homing
Dnve Syringes
Figure 6: A picture of the sampling handling unit taken from the 
AppliedPhotophysics SX 20, Hardware Guide. Syringe A and B indicate where 
sample solutions are added to unit before mixing 25.
The change in intrinsic tryptophan florescence over time (excitation at 290nm, 
emission with a 320nm cutoff filter) at 25°C was recorded. For each reaction at a 
particular concentration, five traces of the signal were collected and averaged. The 
experiments run are listed in table 3.
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Experiment Final MTX 
Concentration (pM)
Time PM Volt
MTX and 2pM C73A/S131C DHFR 1-10 0.1s 480
MTX and 2[iM C73A/S131C DHFR 25-100 2s 480
PYR and 2^M C73A/S131C DHFR 1.25-12.5 0.1s 470
PYR and 2(iM C73A/S 131C DHFR 25-100 10s 470
Table 3: Kinetic experiments that were done using the stopped-flow instrument. The 
final range of concentration of inhibitor obtained after mixing, amount of time the 
data was recorded, and the P.M. volts used for each inhibitor study.
Experimental controls were done before the mixing of enzyme and inhibitor 
(Table 4). This was done to allow for a better approximation of the concentration of 
enzyme inhibitor binds and the percent amplitude of the signal.
CONTROL Syringe A Syringe B
1. Offset Buffer Buffer
2. Enzyme Response Enzyme Buffer
3. Methotrexate (MTX) Response Buffer MTX (2-200pM)
4. Pyrimethamine (PYR) Response Buffer PYR
5. Enzyme. Inhibitor complex Response Internal reading
Table 4: Experimental controls of stopped flow experiments to determine kinetics of 
binding of inhibitor to C73A/S131C DHFR. Refer to Figure 1 for position of syringe 
A and B.
To determine the dissociation rates of the inhibitor, 2uM of C73A/S131C was 
pre-incubated with 4uM of an inhibitor and mixed with 350pM(and 700pM) TMP in the 
stopped flow instrument at 600s (MTX) and 100s (PYR). The traces were fitted using 
DYNAFIT4 program 26.
To study the conformational motions of Y127A and 186A DHFR, the same 
protocol was used, keeping the controls, technical settings constant and enzyme and 
inhibitor concentration similar to C73A/S131C.
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3.2 Determination of Inhibitor Binding Kinetics to C73A/S131Cmdcc DHFR 
To determine the conformational motions associated with inhibitor binding to 
C73A/S131Cmdcc, stopped-flow instrumentation together with MDCC fluorescence. 
Equal volumes of 2pM of C73A/S131C DHFR was mixed with 2-200pM of an inhibitor 
in MTEN buffer at pH 7, 25°C in an applied photo physics SX20 stopped flow kinetics 
instrument with 1mm slit.
The change in MDCC fluorescence over time (excitation at 419nm, emission with 
a 450nm cutoff filter) at 25°C was recorded. A summary of the experiments, inhibitors 
and time scale used are listed in (Table 5). Controls were done using the same parameters 
and procedure as the C73A/S131C experiment; refer to Table 4 in material and methods 
chapter 3, section 3.1
Experiment Final MTX 
Concentration (pM)
Time PM Volt
MTX and C73A/S131Cmdcc DHFR 1-10 0.1s 360
MTX and C73A/S131Cmdcc DHFR 1-100 10s 360
PYR and C73A/S131Cmdcc DHFR 1.25-12.5 0.2s 370
PYR and C73A/S131 Cmdcc DHFR 1.25-100 10s 370
Table 5: Kinetic experiments for 2pM C73A/S131Cmdcc DHFR that were carried 
out in the stopped-flow instrument. The final range of concentration of inhibitor 
obtained after mixing, amount of time the data was recorded, and the P.M. volts 
used for each inhibitor study.
To determine the dissociation rates of the inhibitor, 2uM of C73A/S131Cmdcc 
was pre-incubated with 4uM of an inhibitor and mixed with 350pM(and 700pM) TMP in 
the stopped flow instrument at 600s (MTX) and 100s (PYR). The traces were fitted using 
DYNAFIT4 program. A similar protocol was followed to study the conformational 
motions associated with binding for I86Amdcc and Y127Amdcc DHFR.
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3.3 Analysis of Data using DYNAFIT 4 program
Dynaflt4 is a program used to perform nonlinear least squares regression fitting of 
enzyme kinetic data to a set of chemical equations. In this context the experimental data 
analyzed are reaction regression curves of time (x-axis) versus fluorescence (y-axis).
The averaged individual progression curve data obtained from the reaction of 
2pM of DHFR with a particular concentration of inhibitor c in stopped-flow 
instrumentation are analyzed together; this is a “global fit”. Script files are used to fit the 
data to a set of chemical reactions (fig7).
The same scripts are used for 186A and Y127A. Refer to Appendix III to view the
scripts used for low concentrations and high concentration fits of the progression curves 
from the reaction of enzyme with inhibitor for the unlabeled enzyme and the global fit
scripts for all the concentrations from the labeled enzyme reactions.
Global Fit the progress of C73A/S131C DHFR vs MTX at 0.1s 
[task]
data - progress 
task > fit
[mechanism]
E + MTX o — > EMTX : kl k-1
EMTX ----9- E ’MTX : k2
[constants] ; units: uH, sec
kl - 50? 
k-1 - 0.01 
k.2 m 10
Chemical 
Equation for 
data fitting
[concentrat i ons] 
E - 1.5? 
EMTX -0.É
; units: uM
[responses] ; percent product/nM substrate
E - 0.686?
MTX - -0.0209 
EMTX - 0.238?
E 'MTX- 0.2?
[data]
d t rectory AJsers/Mari e/Desktop/Data/Low 
file 10.1s.txt I offset 7.471 concentrâtton MTX »1 
d i rectory /Users/Mart e/Desktop/Data/Low 
file 1.50.07s.txt I offset 7.37|concentrâtton MTX - 
d i rectory /Users/Mar i e/Desktop/Data/Low 
file 20.06s.txt I offset 7.32Iconcentrâtion MTX - 2 
d t rectory /Users/Mar t e/Desktop/Data/Low 
¡file 2.50.1s.txt (concentration MTX »2.5 I offset € 
d t rectory /Users/Mar i e/Desktop/Data/Low 
file 40.05s.txt I concentration MTX -4 I offset 7.29 
d t rectory /Users/Mar i e/Desktop/Data/Low 
file 50.04s.txt Iconcentrâtton MTX »5 I offset 7.26 
[output]
d t rectory /Users/Mar t e/Desktop/output/WT.715/0.1
Experimental
control
predictions
Individual 
reaction traces 
at varying 
concentrations 
in a global fit
Figure 7: Sample script used to globally fit individual progress curves obtained from 
the reaction of 2pM of C73A/S131C DHFR with varying MTX concentrations.
c Inhibitor refers to methotrexate (MTX) and Pyrimethamine (PYR)
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Results
1. Characterization of DHFR
1.1 Determining Concentration of Purified I86A DHFR DNA Plasmid
Concentrations of the two samples of plasmid purified using QIA miniprep kit were high 
enough to send for sequencing (Table 6).
Purified Plasmid Label Expected Mutations Concentration (ng/pl)
NG1 I86A 49.9
NG2 I86A 19.9
Table 6: Concentration in ng/pl of I86A DHFR DNA plasmid, purified using the 
QIA DNA mini prep- kit.
1.2 Sequencing Results of I86A Mutant Construct
To confirm the introduction of the I86A mutation into C73A/S131C DHFR, the purified 
plasmid amino acid sequence was aligned with the C73A/S131C DHFR sequence. From 
Table 1, both NG1 and NG2 (NG2 data not shown) plasmids had the mutation and 
maintained the fluorescent tag site already present (Fig 8).
I 8 6A_NG1 MISHIVAMDE 
1 1 1 1 1 1 1 1 1 1
NRVIGKDNRL PWHLPADLAY FKRVTMGHAI VMGRKT FEAI 50
Wild_type MISHIVAMDE
1 1 1 1 1 1 1 1 1 1 
NRVIGKDNRL
1 1 1 1 1 1 1 1 1 1
PWHLPADLAY
1 1 1 1 1 1 1 1 1 1 
FKRVTMGHAI
1 1 1 1 1 II 1 1 1 
VMGRKTFEAI 50
18 6A_NG1 GRPLPGRDNV 
1 1 1 1 1 1 1 1 1 1
W T G N R S F R P e g J l v l h s l e EVKQWflASRA DEVFIIGGAE 100
W±ld_type GRPLPGRDNV
1 1 1 1 1 1 1 1 1 1
W T G N R S F R P
1 1 ■  1 1 1 1 1 1 1
e g J l v l h s l e
1 1 1 1 1 ■  1 1 1 1
e v k q w | a s r a
1 1 1 1 1 1 1 1 1 1
DEVFIIGGAE 100
18 6A_NG1 LFRATMPIVD RLYVTKIFAS FPGDTFYPPI ■d d e w e i v s y TPGGKDEKNP 150
Wild_t.ype LFRATMPIVD
1 1 1 1 1 1 1 1 1 1 
RLYVTKIFAS
1 1 1 1 1 1 1 1 1 1
FPGDTFYPPI
■ 1 1 1 1 II 1 1 1
|d d e w e i v s y
! 1 1 1 1 1 1 1 1 1
TPGGKDEKNP 150
18 6A_NG1 YEHAFIIYER KKAK 164
Wild_type
1 1 II II 1 1 II 
YEHAFIIYER
1 1 1 1
KKAK 164
Figure 8:Amino acid alignment sequencing results showing the introduction of I86A 
mutation in the C73A/S131C DHFR purified DNA plasmid introduced by 
mutagenesis. Green amino acids are the fluorescent tag site C73A/S131C and the 
mutation of interest I86A is shown in red. Biology Bench work was used for the 
alignment The nucleic acid sequence is in the Appendix fig 30.
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1.3 SDS-PAGE characterization of WT and I86A constructs
The molecular weight (MW) of DHFR is ~ 18 kDa. The SDS-PAGE (Fig9) shows two 
bands on the gel for C73A/S131C and I86A and Y127A constructs. The lowest band was 
at about 18kDa MW and the highest band at 36kDa indicates a dimer. The EZ protein- 
ladder is shown next to the gel (Refer to Appendix III for SDS-PAGE gels showing 
labeled C73A/S131C, I86A and Y127A protein).
A B C D E F G H  I J H K A - Flow throughl 
B- Lysate
C- Flow through 2 
D- C73A/S131C (1)
E -  C73A/S131C (2)
F- Ladder 
G- I86A lysate 
H- I86A Flow through 1 
I- I86A protein 
J -  Y127 protein 
K -  I86A Protein
kDa
-m o  
-66 2
-450
-3 5 0
-2 5 0
-1 6 4
- 14.4
Figure 9: SDS-PAGE gel of C73A/S131C, I86A and Y127A proteins, using 4X- 
loading dye (lOul Dye and 30ul sample). EZ protein ladder shows the MW sizes and 
position
2. Kinetic Analysis of Conformational Motions Associated with Inhibitor Binding 
to DHFR
In previous findings27, I86A and Y127A mutations were introduced to two 
distinct regions distant from the DHFR active site. The mutant constructs retained 
catalytic activity (kcat) compared to the wild type (WT) but showed a change in the 
inhibitor constant (Ki); the potency of the inhibitor, that was ligand specific to 
methotrexate (MTX) and pyrimethamine (PYR) (Table 7).
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c^at (s )^ Kj (mtx) (nM) Ki (pyr) (nM)
WT 11 0.010 0.018
I86A 2.4 0.15 0.23
Y127A 10 0.17 0.084
Table 7: kc»t(s l) and Ki(nM) of WT, 186A and Y127A for methotrexate (MTX) and 
pyrimethamine (PYR) 21
This validated the hypothesis that residues distal from the enzyme active site 
played a role in ligand specificity and binding. However, how these allosteric mutations 
affect inhibitor binding and specificity is not known. One hypothesis is that the 
mutations may have an effect on the conformational changes and rates associated with 
inhibitor binding and therefore affect inhibitor potency and specificity when compared to 
the WT.
To study the effects of the mutations on conformational changes associated with 
binding, intrinsic tryptophan and extrinsic (MDCC) fluorescence in combination with 
stopped-flow instrumentation is used. Bs. DHFR has a total of three tryptophans (Trp 22, 
Trp 85 and Trp 135) 22 27. Trp 85 and Trp 135 are located distant from the ligand -binding 
site, while Trp 22 is located on a loop that aligns to the active site Met 20 loop in Ec. 
DHFR. It is not clear which tryptophan responds to inhibitor binding, however studies 
done, show that the Ec. DHFR exhibits three conformational states (closed, occluded and 
open) 1 28 and when a extrinsic fluorophore was attached to the Met 20 loop on the Ec. 
DHFR two native conformations were observed during binding of MTX to DHFR 29. It is 
very likely that Trp 22 mostly responds to inhibitor binding, as was seen for the Met 20 
loop and the combination of the three tryptophans is responsible for the overall signal 
detected.
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Previously, the development of a fluorescently labeled DHFR allowed for the 
study of conformational changes associated with MTX binding22. A minimal model was 
determined for MTX binding to two different conformations (E and E’) of DHFR. It 
included an induced fit model as well as a conformational selection pathway. The 
induced fit model involves the inhibitor binding to one conformer (E or E’) and induces a 
conformational change to a more energetically favored conformation20. The 
conformational selection pathway is where a particular conformation (E’ or E) is selected 
for binding 31 to form the enzyme-inhibitor complex. The two conformations are thought 
to be in equilibrium 32 33. (FiglO)
k,= 23pM ls 1
E + MTX EMTX
k_,= 0.01s' K
k k2= 9s 1
N , ..............-i -i 'k4= 0.067(jM's '
E’ + MTX E’MTX
k.4=0.01s ‘
Figure 10: Minimal model for the binding of MTX to E and E \ MTX binding to E 
(kl) or E’ (k4) is the binding event step. The induced fit model relates to (kl and k2) 
or (k4 and k-2). Conformational selective model fits for (k3 and k4) or (k-3 and kl). 
The conformational equilibrium is indicated by (k3 and k-3). The binding affinity 
rate constants and conformational change rate constants are from the previous 
study of the fluorescently labeled DHFR.22
A fluorescent label (MDCC) was covalently attached to the modified 
C73A/S131C DHFR (Fig 11) and conformational changes associated with MTX binding 
that were different from those observed from intrinsic tryptophan fluorescence were 
confirmed. The conformational changes recorded from changes in MDCC extrinsic
21
fluorescence were associated with MTX binding to E’ and the changes in intrinsic 
tryptophan fluorescence overtime, to MTX binding to E.
Figure 11: A cartoon (left) and surface (right) representation of the structure 
ofUs.DHFR (PDB ID: 1ZDR). Residue 131, the site of labeling, is shown as a 
magenta sphere. The MTX binding site is labeled in the surface representation. Data 
shown is from previously published work from Goodey et al.22
3. Methotrexate (MTX) binding to DHFR
3.1 MTX Binding to C73A/S131C, I86A and Y127A DHFR
To study the events occurring during methotrexate (MTX) binding to 
C73A/S131C, I86A and Y127A DHFR (E), 2pM of enzyme (C73A/S131C, I86A and 
Y127A separately) was mixed with 2-200pM of MTX in stopped-flow instrumentation in 
equal volumes and the change in intrinsic fluorescence intensity over time was recorded 
(excitation 290nm, emission 320nm cutoff filter). For all MTX concentrations, a decrease 
in fluorescence over time was observed, similar to previous research 22. The individual
binding
site
MTX
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traces from the different concentrations were fit to an induced fit two-step model, similar 
to that of the previous study (fig 12), on a “global fit” in DYNAFIT4 program.
ki
E  + M T X  --------------^  E M T X^ -----------------
k" N
k 2 k -2
N
E ’M T X
Figure 12: Minimal model used for the binding of PYR to E detected by intrinsic 
tryptophan fluorescence .The induced fit model relates to (ki and k2).
A large concentration dependent decrease in tryptophan fluorescence emission
over time associated with MTX binding was observed during binding of low 
concentrations (2-20pM) of MTX to C73A/S131C, I86A and Y127A (Fig 13). It is 
concentration dependent because the rate of binding increases along with MTX 
concentration. These binding event traces were fit using Dynafit4 program.
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A. B.
1 5p.M :<>hm
2 5 nM
4(i,M
5MM
Time ($)
D.
E+MTX E.MTX
1 j5»M
2 (>MM
2j|xM
4m.\1
5yM
Figure 13: The binding event step (D) with a large MTX concentration dependent 
decrease in fluorescence emission over time is observed with different association 
rates (ki) for A. C73A/S131C (60pM 1 s'1), B. I86A (71pM 1 s 1), and C. Y127A 
(32pM_1 s'1). Low concentrations (2-20pM) of MTX are rapidly mixed with 2pM of 
enzyme in equal volumes and the traces were “globally fit” using DYNAFIT 4 
program.
A second small MTX concentration independent decrease in fluorescence 
emission over time was observed for large concentrations (50-200pM) of MTX binding 
to all three enzymes (C73A/S131C, I86A and Y127A). It is concentration independent 
because the rate does not change with increasing concentration of MTX. The first large 
decrease happened too fast for the higher concentrations of MTX and was over within the
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dead time of the instrument while the second decrease was too small to be detected for
lower MTX concentrations. (Fig 14). 
A
■z
yÿ
D
E.MTX
Time (s)
c
2.VM
E’.MTX
B
Time (s)
25 nM
25*iM
Time (s)
Figure 14: A small MTX concentration independent decrease in fluoresce emission 
over time for is observed with different rates (to) for A. C73A/S131C (9 s 1), I86A 
(23s1) and Y127A (10 s'1). High concentrations of MTX (50-200pM) are rapidly 
mixed with 2pM of enzyme in equal volumes and the Traces were “globally fit” 
using a one directional step model (D) on DYNAFIT 4 program.
The dissociation rates were determined by using Trimethoprim (TMP) to displace 
the enzyme MTX complex for C73A/S131C, I86A and Y127A separately in stopped- 
flow instrumentation as was done previously by Goodey study 22. Enzyme (2pM) was 
pre-incubated with MTX (4pM) and mixed in the stopped-flow instrumentation with 
350pM and 700pM of TMP. Traces (600s) showed an increase in tryptophan 
fluorescence emission indicating displacement of MTX by TMP and were sufficiently fit
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using a single exponential equation (not shown) and confirmed using Dynafit4 program 
(Figl 5).
0 200 400 600
Time (s)
Figure 15: An increase in fluorescence emission over time is observed for the 
dissociation of MTX from the enzyme complex. C73A/S131C (A), I86A (B) and 
Y127A (C) all have different rates with different amplitudes. Y127A having the 
highest %change amplitude (k -i). The increase shows the displacement of MTX by 
varying concentrations (350pM (not shown) and 700pM) of TMP from the EMTX 
complex and was obtained by mixing pre-incubated enzyme (2pM) with MTX 
(4pM) with (350pM and 700pM) TMP in the stopped flow instrumentation.
The first decrease is attributed to MTX binding to E for all enzymes with an 
association rate (ki) of 60pM'1s'1(C73A/S131C), TlpM 'V1 (I86A) and 32pM'1s' 
1(Y127A). The bOpM'V1 ki rate constant obtained for C73A/S131C differed from the 
Goodey Paper at 23 PM'1 s'1.This difference could be as a result of inclusion of the higher 
concentrations in the single exponential fittings, something we did not do in this work.
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When comparing the mutants to C73A/S131C, the I86A association rate varied 
slightly to C73A/S131C; it was showed an increase with no significant change in the % 
amplitude. The ki of Y127A differed significantly to both C73A/S131C and 186A with a 
change in the % amplitude. The fitting provided an approximation of the percentage of 
conformer E present in the total amount of enzyme, prior to binding of MTX.
The second decrease is associated with a conformational change from the EMTX 
complex to E’MTX it was however not clear what the best value for the k2 is, given the 
small amplitude of the signal. The conformational change step for 186A was faster at 
23s'1 compared to 9s'1 for C73A/S131C and 10s’1 for Y127A. (Table8). The % amplitude 
was lower for I86A compared to Y127A, accounting for the faster conformational change 
rate constant
Dynafit Data for MTX C73A/S131C I86A Y127A
ki (pM'V1) 60±3.0 71±2.0 32±1.0
k2 (s ') 9±1.0 23±3.0 10±0.6
%E concentration 71±16.0 78±3.0 83±10.0
% Amplitude of 
fluorescent signal of ki
3.40 2.60 1.10
% Amplitude of 
fluorescent signal of kz
1.10 0.03 1.50
Table 8: Parameters for C73A/S131C, I86A and Y127A obtained from DYNAFIT4 
program. Association rates, ki (pM'V1), conformational change, k2 (s'1) 
concentration of E prior to binding in the total amount of enzyme used in the 
experiment. The % amplitude of the signal was calculated by the change in 
fluorescence divided by the initial fluorescence at time zero. The standard error 
shown is a regression error from fitting.
Dissociation rates (k-i) of 0.01s'1(C73A/S131C), O.Olôs'^ISÔA) and 0.02s'1 
(Y127A) were obtained from fitting the traces to a single exponential equation (data not 
shown) and confirmed using Dynafit4 program (Table 9). The % amplitude in the
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fluorescent signal was higher for Y127A indicated a larger change in the dissociation rate 
compared I86A.
k-i (s'1) (MTX) C73A/S131C I86A Y127A
350pM 0.011 0.017 0.024
700pM 0.010 0.017 0.025
Average 0.010±0.007 0.017±0.004 0.024±0.005
%Amplitude of -0.15 -0.15 -0.18
fluorescent signal
of k-i
Table 9: Dissociation rates (k-i) for C73A/S131C, 186A, and Y127A obtained from 
DYNAFIT4 program, for the varying concentrations of TMP after mixing with pre­
incubated E (2pM) and MTX (4pM). Final k-i values are calculated by taking the 
average of values from 350pM and 700pM TMP. The % amplitude of the 
fluorescent signal for Y127A was higher compared to I86A and C73A/S131C. 
Errors indicate standard deviations from three sets of actual data.
For binding of MTX to conformer E, the mutants did affect the binding rate 
constants (ki and k-i) and conformational change step (k2) compared to C73A/S131C 
(modified wild type). Although I86A had a similar ki to C73A/S13C, this mutation did 
affect the conformational change step. In the case of Y127A, the binding rate constant ki 
was significantly slower compared to C73A/S131C and I86A and a much faster k-i.
In the case of the I86A mutation, an increase in both the forward and reverse rate 
constant is seen. For Y127A we see a decreases in the forward rate and an increases the 
reverse. This may answer the question of how the mutations affect MTX binding but it 
does not answer what role they play in the allosteric regulation of the global protein 
dynamics.
3.2 MTX Binding to MDCC Labeled DHFR
Varying concentrations of MTX (2-200pM) was mixed with 2pM of MDCC 
labeled DHFR)(E’), (C 73A /S131C mdcc, I86A mdcc and Y 127A mdcc) in stopped-flow
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instrumentation in equal volumes and the change in MDCC fluorescence emission over 
time was recorded (excitation 419nm, emission 450nm cutoff filter). Similar to MTX 
binding to E and to the previous fluorescent labeled DHFR studies22, a large 
concentration dependent decrease in fluorescence over time was observed during MTX 
binding. This decrease is not the same conformational change associated with MTX 
binding to E, instead it is associated with MTX binding to E \ The binding affinity rate 
constants (k4 and k-4) were very different from those recorded for changes in intrinsic 
tryptophan fluorescence, attributing this particular change to MTX binding to conformer 
E \
The individual traces from the different concentrations were fit to a second order 
rate constant in a global fit on DYNAFIT4. The conformational selection step from the 
minimal model (fig 10), that includes an association rate (k4) and dissociation rate 
constant (k-4), is the event represented here (Fig 16). There is no conformational change 
step observed for E’MTX to EMTX as was seen for E from changes of intrinsic 
tryptophan fluorescence.
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Figure 16: The binding event step for binding of MTX to E’ (D) with a large MTX 
concentration dependent decrease in fluorescence emission over time is observed 
with different association rates (k4) for A. C73A/S131C (0.069p m 1 s ' 1) ,  B. I86A 
( 0 . 0 7 4 p m 1 s ' 1) ,  and C. Y127A (0.070pM_1 s'1). Varying concentrations of MTX (2- 
200pM) are rapidly mixed with 2pM of enzyme.
Dissociation rates were determined by using Trimethoprim (TMP) to displace 
MTX from the E’MTX complex for C73A /S131C mdcc, I86A mdcc and Y 127A mdcc 
separately in stopped-flow instrumentation as was done for conformer E. Enzyme (2pM) 
was pre-incubated with MTX (4pM) and mixed in the stopped-flow instrumentation with 
350pM and 700pM of TMP. Traces (600s) showed an increase in tryptophan 
fluorescence emission indicating displacement of MTX from conformer E’ by TMP and 
were sufficiently fit using a single exponential equation (not shown) and confirmed using 
Dynafit4 program (Figl7).
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Figure 17: An increase in fluorescence emission over time is observed for the 
dissociation of MTX from E’MTX. C73A/S131Cmdcc (A), I86Amdcc (B) and 
Y127Amdcc (C) all have different rates (k -4). The increase shows the displacement 
of MTX by varying concentrations (350pM and 700pM) of TMP from the E’MTX 
complex and was obtained by mixing pre-incubated enzyme (2pM) and MTX (4pM) 
with (350pM and 700pM) TMP in the stopped flow instrumentation.
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Dynafit Data for MTX C73A/S131Cmdcc I86Amdcc Y127Amdcc
k4 (pM 's1) 0.069±0.0005 0.074±0.0004 0.070±1
k-4 (s'1) 0.010±0.0001 0.023±0.0001 0.026±0.0002
%E’ concentration 38±0.1 25±0.1 23±0.1
% Amplitude of 
fluorescent signal
15 14 9
% Amplitude of 
fluorescent signal
-5.9 -11.5 -1.5
Table 10: Parameters for C73A/S131Cmdcc, I86Amdcc and Y127Amdcc obtained 
from DYNAFIT4 program. Association rates, k4 (pM'V1), dissociation rates, k-4 (s' 
!), concentration of E’ prior to binding in the total amount of enzyme used in the 
experiment is obtained from DYNAFIT fitting, and the % amplitude of the signal 
calculated from the change in fluorescence divided by the initial fluorescence at time 
zero. The standard errors shown are regression errors from fitting.
This data confirms the previous Goodey 22study that Bs. DHFR exists in two 
different conformers (E and E’) that have different binding affinity rate constants. For all 
the enzymes (C73A/S131C, I86A, Y127A) MTX binding to E has a faster association 
rate constant than E \ There are two conformational change events happening in the case 
for E; a conformational change associated with binding of MTX followed by a 
conformational change from EMTX to the more stable complex E’MTX. The k-2 was not 
easily resolved for the case of E’ where we only see a conformational change associated 
with binding to form the E’MTX complex.
During binding of MTX to both E and E’ we see similar conformational motions 
for the mutant (I86A, Y127A) compared to C73A/S131C (the modified wild type). The 
effects of the mutations are visible from changes in binding and conformational rate 
constants compared to C73A/S131C (Fig 18).
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A k,= (jOhM 's"1
E + MTX EMTX
B k,= 71(xM's '
E + MTX- .....  ^  EMTX
k ,=  0.010s 1
3 i r u k .k,= 9s'1
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E’ + MTX^  ^  E’MTX
k 4 =0.010s 1
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Figure 18: Binding Mechanism of MTX to E and E’ for A. C73A/S131C, B. I86A 
and C. Y127A showing the Binding rates and conformational change rates.
The ki and k-4 differ the most for I86A with a large changes in % amplitude to 
C73A/S131C, indicating they are different rates from those of C73A/S131C. The biggest 
change we see for Y127A is in the % amplitudes of k4 and k-4 . The k4 is within the same 
range as C73A/S131C however they are different because the % amplitudes are different.
4. Pyrimethamine (PYR) binding to DHFR
4.1 PYR Binding to C73A/S131C, I86A and Y127A DHFR 
A similar method to section (2.1) in results Chapter 2 for the binding of MTX to 
DHFR was applied to study conformational changes associated with pyrimethamine 
(PYR) binding to C73A/S131C, I86A and Y127A.
Upon binding of low concentrations (2-25pM) of PYR, a large concentration- 
dependent increase in intrinsic tryptophan fluorescence emission overtime was observed
33
for C73A/S131C. Yet, when compared to C73A/S131C and I86A, Y127A revealed a 
small increase with a very small amplitude signal (Fig 19). From the MTX studies, we 
know that conformational motions of E are detected by intrinsic tryptophan fluorescence; 
it is safe to assume that this conformational change is attributed to PYR binding to 
conformer E.
12.5(iM
7.5jiM  
5.0nM 
2.5(xM 
1 .25mM
Time (s)
Figure 19: An increase in intrinsic tryptophan fluorescence emission over time is 
observed for the binding of PYR to E (D) when low concentrations (2-20pM) of PYR 
are rapidly mixed with 2pM of enzyme in equal volumes and the traces “globally 
fit” using DYNAFIT 4 program. The association rate constants (ki) were different 
for A. C73A/S131C (35pM 1 s 1), B. I86A(47pM 1 s 1), and C. Y127A(87pM 1 s 1).
The increase in intrinsic tryptophan fluorescence emission over time is a 
concentration dependent increase because the rate of binding increases with increasing 
concentrations of PYR. This is the binding event step.
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After the binding event was over, a second conformational change that showed a 
decrease in intrinsic tryptophan fluorescence over time was observed for higher PYR 
concentrations (50-200pM). For all three enzymes, this decrease was concentration 
independent because the rate of the event did not change with increasing concentrations 
of PYR and is therefore the conformational change of the complex EPYR to E’PYR.
When the conformational change rates (k2) for the mutants are compared to 
C73A/S131C (the modified wild type); the rates for the mutants are much slower and at a 
slower time scale than C73A/S131C. Y127A shows the slowest conformational change at 
a 100s range to I86A at 20s and C73A/S131C at 10s. (Fig20).
T im e  (s) T im e  (s)
T im e  (s)
Figure 20: A small PYR concentration independent decrease in tryptophan 
fluorescence emission over time is attributed to the conformational change of 
complex EPYR to E’PYR (D) with different rates (k2)for A. C73A/S131C (2.80 s 1), 
I86A (0.30 s 1) and Y127A (0.08 s'1). High concentrations of MTX (50-200pM) are 
rapidly mixed with 2pM of enzyme in equal volumes and the Traces were “globally 
fit” using a one step model (D) on DYNAFIT 4 program.
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The binding event observed with an increase in tryptophan fluorescence happens 
very fast that it is over within the dead time of the instrument for high concentrations. 
Similar to the MTX experiment, the optimal value for k2 was difficult to obtain for 
C73A/S131C and I86A because of the small change in the tryptophan fluorescence 
signal.
To displace PYR from the enzyme complex (EPYR), a competition experiment 
was done, by mixing pre-incubated enzyme (2pM) and PYR (4pM) with varying 
concentrations of TMP (350pM and 700pM) in the stopped flow instrumentation. A large 
decrease in tryptophan fluorescence emission over time (100s) was recorded. The 
decrease indicates the displacement of PYR by TMP, since the change in the overall 
tryptophan fluorescence signal from the binding event was a large increase. The values of 
k-i were obtained by fitting the traces to a single exponential (not shown) and confirmed 
on Dynafit 4. (Fig21)
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Figure 21: A decrease in fluorescence emission over time is observed for the 
dissociation of PYR from the enzyme complex EPYR (D). C73A/S131C (A), I86A 
(B) and Y127A (C) all have different dissociation rates (k -1). This was obtained by 
mixing pre-incubated enzyme (2pM) with MTX (4pM) with (350pM and 700pM) 
TMP in the stopped flow instrumentation.
The first phase increase is attributed to PYR binding to E for all enzymes with an 
association rate (ki) of 35pM'1s'1 (C73A/S131C), 47pM'1s‘1 (I86A) and 87pM'1s'1 
(Y127A). The association rates were obtained from a “global fit “ of the traces on 
DYNAFIT4. Y127A has a significant effect on the forward binding affinity rate constant 
when compared to C73A/S131C and I86A, with a decrease in the % amplitude signal. 
The small change in tryptophan signal along with a very fast association rate, may 
suggest that Y127A has a different conformational change associated with PYR binding, 
however the nature of this conformational change is not known. (Table 11)
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The second phase small decrease in intrinsic tryptophan fluorescence is associated 
with a conformational change step from the EPYR complex to the E’PYR with a 
conformational rate of 2.80 s-1 (C73A/S131C), 0.30 s-1 (I86A) and 0.16s-l (Y127A). 
Similar to the conformational change rate for EMTX to E’MTX, it was not clear what the 
optimal k2 value was for C73A/S131C and I86A, since the amplitude of the signal was 
so small (Table 11). However the k2 for the mutants were significantly slower than 
C73A/S131C and they showed a decrease in the % amplitude signal.
Dynafit Data for PYR C73A/S131C I86A Y127A
ki (pM'V) 35=4=1.1 47±1.2 87±9.1
fa (s ') 2.80±0.39 0.30±0.03 0.08±001
%E concentration 74±0.12 86±0.30 85±0.14
% Amplitude of 
fluorescent signal ki
-3.1 -4.4 -1.5
% Amplitude of 
fluorescent signal k2
0.07 0.10 0.26
Table 11: Kinetic parameters for PYR binding to C73A/S131C, I86A and Y127A 
obtained from DYNAFIT4 program. Association rates, ki (pM'V1), conformational 
change, k2 (s'1) concentration of E prior to binding in the total amount of enzyme 
used in the experiment, and the % amplitude of the signal. The standard error 
shown is a regression error from fitting.
Dissociation rates (k-i) of 0.21s'1(C73A/S131C), 0.17s'1 (I86A) and 0.14s'1 
(Y127A) were obtained from fitting the traces to a single exponential equation and 
confirmed using Dynafit4. Y127A showed a decrease in the % amplitude signal, 
indicating the biggest difference in k-i when compared to C73A/S131C and I86A. This 
rate as well as the conformational change observes is different from the other two 
enzymes. (Table 12)
38
k-i (s'1) (MTX) C73A/S131C I86A Y127A
350pM 0.21 0.017 0.15
700pM 0.20 0.016 0.14
Average 0.2U0.01 0.17±0.01 0.15±0.01
Table 12: Dissociation rates (k-i) for C73A/S131C, I86A and Y127A obtained from 
DYNAFIT4 program, for the varying concentrations of TMP after mixing with pre­
incubated E (2pM) and PYR (4pM). Final k i values are calculated by taking the 
average of values from 350pM and 700pM TMP. The errors shown are calculated 
from the actual data.
The conformational motions of DHFR (C73A/S131C, I86A and Y127A) 
associated with PYR binding, detected from changes intrinsic tryptophan fluorescence, 
revealed the presence of two conformations of DHFR. This aligned with the data 
obtained from MTX binding to DHFR and a similar model can be used for PYR binding 
(fig. 22).
E + PYR
ki
k-i
EPYR
h
k 2 k -2
N|
E'PYR
Figure 22:Minimal model used for the binding of PYR to E detected by intrinsic 
tryptophan fluorescence .The induced fit model relates to (ki and k2).
4.2 PYR Binding to C73A/S131CMDCC, I86AMDCC and Y127AMDCC
DHFR
To study the conformational motions of DHFR from changes in MDCC 
fluorescence over time, PYR (2-200pM) was mixed with 2pM of MDCC labeled DHFR
39
(C73A/S131Cmdcc, I86Amdcc and Y127Amdcc) in the stopped-flow instrumentation at 
equal volumes and the change in MDCC fluorescence over time was recorded (excitation
419nm, emission 450nm cutoff filter). A large concentration dependent decrease in 
fluorescence over time was observed during PYR binding to C73A/S131Cmdcc and 
Y127Amdcc. A large concentration dependent increase is observed for PYR binding to 
I86AMDCc,this is a very different conformational change and may give an explanation for 
the large increase in in the inhibitor constant (Ki) seen in the ligand specificity study 21.
(Fig23)
Time (s)
Figure 23: D shows the binding event of PYR to E \ A large PYR concentration 
dependent decrease in MDCC fluorescence emission over time is observed with 
association rates (lu) for A. C73A/S131Cmdcc (O.SSpM'V1) and C. Y127Amdcc 
(1.15pM'* s'1). A large PYR concentration increase in MDCC fluorescence is 
observed for B. I86Amdcc (0.83pM'1s 1). Varying concentrations of PYR (2-200pM) 
are rapidly mixed with 2pM of enzyme.
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The decrease in MDCC fluorescence was not the same conformational change 
associated with PYR binding to conformer E for C73A /S131C mdcc and Y 127A mdcc, 
where we see an increase in intrinsic tryptophan fluorescence. It is a conformational 
change associated with PYR binding to E’ and both C73A /S131C mdcc and Y 127A mdcc 
have a different association rate constant (k4) compared to the ki for PYR binding to 
conformer E.
In the case of I8 6 A mdcc, we see an increase in both MDCC fluorescence and 
intrinsic fluorescence emission over time, a conformational change associated with PYR 
binding to E’ and E respectively. We attribute the increase in MDCC fluorescence to the 
binding event associated with E’ because a different association rate constant (k4) is 
obtained compared to the ki of PYR binding to E.
For higher PYR concentrations (50-200pM), after the binding event was over we 
observe a small decrease in MDCC fluorescence over time that was concentration 
independent. The rate of the event does not increase with increasing PYR concentrations 
and is attributed to the conformational change of the E’PYR complex to EPYR, a step not 
seen during MTX binding to E \ The % amplitude of MDCC signal for 186A differes 
significantly from C73A/S131C and Y127A suggesting a different conformational 
change observed. (Fig 24)
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Time (s)
100 nM
Figure 24: D shows the conformational change step for E’PYR to EPYR. A PYR 
concentration independent decrease in MDCC fluorescence emission over time is 
observed with rates (k-2) for A. C73A/S131Cmdcc (0.03s*1), C. Y127Amdcc (0.11s*1) 
and B. I86Amdcc (O.OSpM'V1). High concentrations of PYR (50-200pM) are rapidly 
mixed with 2pM of enzyme.
A similar competition experiment for MTX in section 3.2 was used to determine 
the dissociation rates of PYR from the E’PYR complex. Trimethoprim (TMP) to displace 
MTX from the E’MTX complex for C73A /S131C mdcc, I86A mdcc and Y 127A mdcc 
separately in stopped-flow instrumentation; Enzyme (2pM) was pre-incubated with MTX 
(4pM) and mixed in the stopped-flow instrumentation with 350pM and 700|iM of TMP.
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Traces (100s) showed an increase in tryptophan fluorescence emission indicating 
displacement of PYR from conformer E’ by TMP and were sufficiently fit using a single 
exponential equation (not shown) and confirmed using Dynafit4 program (Fig25). We 
see an increase in MDCC fluorescence for the dissociation event for I86A mdcc because
the overall signal was a decrease. Y127A mdcc showed the largest decrease in %  
amplitude when compared to I86A and C73A/S131C.
Time (s)
Figure 25: An increase in fluorescence emission over time is observed for the 
dissociation of PYR from E’MTX. C73A/S131Cmdcc (A), I86Amdcc (B) and 
Y127Amdcc (C) all have different rates (k -4). The increase shows the displacement 
of MTX by varying concentrations (350pM and 700pM) of TMP from the E’PYR 
complex and was obtained by mixing pre-incubated enzyme (2pM) and PYR (4pM) 
with (350pM and 700pM) TMP in the stopped flow instrumentation.
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The binding affinity rate constants were similar for the mutants (Y 127A mdcc and 
I86A mdcc) compared to C73A /S131C mdcc and the conformational change step rate was 
within the same range for all three enzymes (C73A /S131C mdcc, I86A mdcc, Y 127A mdcc). 
We observe a different conformational change associated with PYR binding to E’ for 
I86A mdcc as well as different % amplitude in MDCC fluorescence signal; it is interesting 
that the binding affinity rate constants and the conformational change rate do not differ 
significantly for I86A mdcc C 73A /S13C mdcc and Y 127A mdcc. The major difference is 
observed in the % amplitude of MDCC signal. (Tablel3).
Dynafit Data for PYR C73A/S131Cmdcc I86Amdcc Y127Amdcc
k4 (pM ’s'1) 0.55Ü.1 0.83±0.01 1.15±0.03
k-4 (s'1) 0.16±0.001 0.14±0.001 0.27±0.002
k-2 (s'1) 0.03±0.002 0.05±0.003 O.lliO.OOl
%E’ concentration 39±0.18 25±0.30 30±0.14
% Amplitude of 
fluorescent signal for k4
-4.09 -1.40 1.10
% Amplitude of 
fluorescent signal for k-4
-4.09 -3.04 1.06
% Amplitude of 
fluorescent signal for k-2
-0.54 -0.11 -0.69
Table 13: Kinetic parameters for PYR binding to C73A/S131Cmdcc, I86Amdcc and 
Y127Amdcc obtained from DYNAFIT4 program. Association rates, k4 (pM'V1), 
dissociation rates, k-4 (s'1), conformational change rates k-2 (s'1), concentration of E 
prior to binding in the total amount of enzyme used in the experiment, and the % 
amplitude of the signal are shown. The standard error shown is a regression error 
from fitting.
The data obtained from the MDCC fluorescent experiment of PYR binding to E’, 
confirms the existence of the two conformers observed in the MTX experiments. It is 
therefore suitable to use a similar overall minimal model for the events associated with 
binding of PYR to the two conformers (E and E’) (Fig 26) as was used for MTX (refer to 
figure 10).
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E + PYR EPYR
k3
E’ + PYR
ki
k2 J  p k 2
E’PYR
Figure 26: Minimal model for the binding of PYR to E and E’ similar to MTX 
model. PYR binding to E (ki) or E’ (ki) is the binding event step. The induced fit 
model relates to (ki and to) or (k4 and k-2). Conformational selective model fits for 
(to and k<) or (k-3 and ki). The conformational equilibrium is indicated by (to and 
to).
The nature of the conformational changes observed is not known however the 
different % amplitude in MDCC fluorescence for to, k-4 and to, indicate a different 
conformational change for I86A and Y127A when compared to C73A/S131C with 
different rate constants. (Fig 27)
k ,=  3 5 i iM 's - ‘ B
E + PYR ^  ^  EPYR
 ^ k . ,=  0 .2 1 s 1 ft
k-j
1 s-
k^= 2 .80s 1 k ,= 0 . 0 3 s '
k 4= 0 .5 5 | iM 's - '
E’ + PYR ^  E’PYR
k ,=  4 7 n M ls l
E + PYR —  ^  EPYR
k
k .,=  0 .17s-'
k ,=  0 .30 s ' k . ,=  0 .0 5 s '
k 4= 0 .8 8 n M  >s-'
E’ + PYR ~  ^  E’PYR
k_ ,=0 .14s"'
k ,=  87|xM 's"'
E + PYR — ^  EPYR
\ k  ,=  0 .15s-'
•^3 k ,=  0 .08s-'
k 4=  l . l S u M ' f '  '
E’ + PYR ^  ^  E’PYR
k j= 0 .2 7 s  1
Figure 27: Binding Mechanism of PYR to E and E’ for A. C73A/S131C, B. I86A and 
C. Y127A
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Summary
1. Conformational Motions Associated with Inhibitor Binding
In this work, we reveal the conformational changes associated with inhibitor binding 
are inhibitor specific. Upon binding of MTX to conformer E of all the DHFR 
(C73A/S131C, I86A and Y127A) we observe a large concentration dependent decrease in 
tryptophan fluorescence over time, while binding of PYR to E shows an increase in 
tryptophan fluorescence. (Fig 28)
A
l.5nM
2.0pM
2.5(iM
4|jM5nM
E + M T x J ^ E .M T X
. -^1
12.5(xM
lO.O(iM
7.5|xM
5.0(iM
2.5(aM
E + PYR ^  EPYR
-^1
Figure 28:Different conformational changes associated with MTX and PYR binding 
to C73A/S131C DHFR detected by intrinsic tryptophan fluorescence. A. MTX 
binding to Conformer E revealed a concentration dependent decrease in tryptophan 
florescence emission. B. PYR binding to E shows an increase in tryptophan 
fluorescence.
Inhibitor binding to the other conformer of DHFR (E’) reveals a different
conformational change compared to E, which was also inhibitor specific. We observe a 
large concentration dependent decrease in MDCC fluorescence for both MTX and PYR
binding to E ’ of C73A /S131C mdcc and Y 127A mdcc. This decrease is different from the
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decrease observed during binding of MTX to E (Fig 29). Although I8 6 A mdcc had a
similar conformational change associated with MTX binding, it showed a completely
different motion (an increase in MDCC fluorescence) during PYR binding (refer to Fig
23).
A
1.5(xM
2.0|iM 
2.5 |iM
4^M
5nM
12.5|iM 
lO-OpM 
2.5 nM 
7.5nM 
5.0|jM
5|j.M
10(iM
25|i,M
50^M
100|xM
Time (s)
2.5^M
10.0(J,M
5.0|iM
1.25
Time (s)
Figure 29: Different conformational changes associated with MTX and PYR binding 
to Y127A DHFR detected by intrinsic tryptophan fluorescence and MDCC 
fluorescence. A. MTX binding to Conformer E. B. PYR binding to E. C. MTX 
binding to Conformer E \ D. PYR binding to E \
MTX and PYR are competitive inhibitors of DHFR that bind in the active site of 
the enzyme and therefore interact with the active site residues. One might assume to 
assume that the conformational change associated with binding of any competitive 
inhibitor of DHFR would not be different across inhibitors. This is not the case as we see
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for MTX and PYR. Although the nature of the conformational change is not known, each 
inhibitor induces a different conformational motion of DHFR upon binding. A structural 
understanding of these ligand induced conformational motions may be potential targets in 
drug design and therefore have implications for structure-based and molecular dynamics 
drug design.
2. Effects of Allosteric Motions on DHFR
2.1 Effects o f Allosteric Mutations on association rate constants
The allosteric mutations affected the binding affinity rate constants of MTX and 
PYR binding to conformer E when compared to C73A/S131C (the modified wild type). 
There was no significant change in the binding affinity rate constants for binding of MTX 
and PYR to E’ for all there enzymes (C73A/S131C, Y127A and I86A). The effects were 
also inhibitor specific, with an increase in the association rates (ki) of MTX and PYR to 
186A and a decrease for MTX to Y127A and an increase for PYR to Y127A.
The most significant difference for Y127A was in the ki, k-i and k4 for MTX and 
ki and k2 during PYR binding. I86A showed the biggest change in k2 and k-4 for MTX 
and k2 for PYR. When we compare both mutants to each other Y127A seems to have a 
larger effect on the association and dissociation rates while I86A affects the 
conformational changes.
The koff/kon values are calculated from the experimental values of k-i and ki for 
conformer E and k-4 and k4 for conformer E’ (Table 13).
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k-i/ki(MTX) nM k-4/k4(MTX) nM k-i/ki(PYR) nM k4/k4(PYR) nM
C73A/S131C 0.17 114.93 6.00 290.90
I86A 0.24 310.81 3.61 168.67
Y127A 0.75 371.42 1.72 234.78
Table 13: k0ff/k0n parameters calculated from binding affinity rate constant resolved 
from kinetic data from stopped-flow experiments.
These values give an estimate of the equilibrium dissociation constants, kD for 
MTX and PYR to E and E \ Based on these estimates the E conformer of C73A/S131C 
has a higher affinity for MTX than E \ This trend is the same for the mutants, Y127A, 
and I86A although when compared to C73A/S131C both mutants show a decrease for 
affinity of MTX.
PYR binds better to DHFR of protozoan species, so it makes sense that DHFR 
from Bs. would have a lower affinity for PYR than MTX. Similar to MTX, the E for all 
three enzymes has a higher affinity for PYR compared to E \
The data aligns with the inhibitor specificity study 21 where we see the allosteric 
mutations affecting inhibitor binding. A small perturbation such as a distal allosteric 
mutation is able to affect the binding affinity rate constants of MTX and PYR to DHFR 
far from the active site. These minimal changes in the rate constants and the 
conformational change rates more information for the effects of the allosteric mutations 
on inhibitor binding.
2.2 Effects o f Allosteric Mutations on the Conformational Equilibrium o f 
DHFR Prior to Inhibitor Binding
The advantage of using DYNAFIT4 program for enzyme kinetic fitting is that, it 
can give a calculation for the concentration of enzyme involved in inhibitor binding. One 
hypothesis of how allosteric mutations affect inhibitor binding and specificity is by
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altering the conformational equilibrium of DHFR. This can be significant if the low 
energy, binding event involves the induced fit pathway as opposed to the conformational 
selection pathway and a shift in equilibrium may alter the presence of the preferred 
conformer for initial inhibitor binding. Kinetic data retrieved from the stopped-flow 
instrumentation experiments, reveal approximations of the % concentration of E and E’ 
prior to inhibitor binding. (Table 14)
%E (MTX) %E (PYR) Overall%E %E’ (MTX) %E’ (PYR)
Overall
%E’
C73A/S131C 71 74 or-u 38 39 ~30
I86A 73 86 ©r-n 25 25 ~30
Y127A 86 85 ~80 23 30 ~20
Table 14: An approximation of the conformational equilibrium of E and E’ prior to 
binding, obtained from DYNAFIT4 kinetic data fitting. The % concentration of 
conformer E available to bind MTX and PYR and % concentration of E’ for MTX 
and PYR binding are shown in the table.
From the data we can estimate that for all DFiFR enzymes (C73A/S131C, Y127A 
and I86A) ~70 % of E and ~30 % of E’ exist in solution. The conformational equilibrium 
prior to inhibitor binding is not affected very significantly by the introduction of 
allosteric mutations. This is just an approximation and cannot rule out fully, a slight shift 
in conformational equilibrium as a factor involved in the role of allosteric residues in the 
regulation of protein motions necessary for ligand specificity and binding.
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Conclusion
We wanted to investigate the effects of distal allosteric mutations on the 
conformational motions of DHFR upon inhibitor binding and validate the previous study 
done to support the effects of allosteric mutations of inhibitor specificity and binding 21. 
It is clear, that the allosteric mutations do affect ligand binding and the conformational 
motions associated with inhibitor binding without altering the conformational equilibrium 
of DHFR prior to binding.
I86A had very similar binding affinity rate constants and conformational change 
rates to C73A/S131C, but affected the conformational motions associated with PYR 
binding to conformer E’; It showed an increase in MDCC fluorescence emission overtime 
compared to the decrease seen for C73A/S131C.
Y127A exhibited very different binding affinity rate constants to C73A/S131C 
and I86A. The association rate constant decreased for binding to MTX while it increased 
for PYR binding. For the conformational change rates, we see a very slow rate, 0.08s"1 in 
the millisecond time scale compared to 2.80s"1 for C73A/S131C. Slowing down the 
conformational change step may affect the binding kinetics of the enzyme. The 
conformational change associated with PYR binding to E, revealed a small concentration 
dependent increase in tryptophan fluorescence over time, which can be attributed to a 
different conformation change compared to that seen for C73A/S131C and I86A.
These mutations are located at sites distal from the active site and do not interact 
with the inhibitor in the binding pocket. Yet, they are able to affect the conformational 
motions associated with inhibitor binding along with the binding and conformational
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change rates. The mutations introduced are also located at different distal sites on the 
enzyme and the effects on DHFR are very different between the two mutations.
It is most likely that allosteric mutations may exert their effects by affecting the 
conformational motions, particularly by slowing them down, speeding up or changing 
them completely as in the case of PYR binding to E’ of I86A. The residues located in the 
mutation regions may exhibit the same effects as the individual mutations and further 
studies on cluster mutations as well as double cluster mutations might reveal more 
information on which conformational motions are severely affected.
Another important factor revealed from this work, was that the conformational 
changes associated with inhibitor binding were different for MTX compared to PYR. It is 
very easy to assume that inhibitors that bind to the same site would induce the same 
conformational change even though they may interact with different active site residues. 
This is not the case, as the conformational changes are inhibitor specific, and also induce 
different conformations when binding to the different conformers. This is relevant for 
structure based drug design, molecular docking and molecular dynamics computational 
studies for drug design, as these motions may be potential drug targets or reveal more for 
design of better and selective inhibitors.
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APPENDIX
Sx 20 Stopped Flow Instrumentation Settings
Light source 150W air cooled Xe arc Lamp
Lamp Stability <0.001 AU peak to peak
SF cell Volume 20pL
Pathlength (Fluorescence) 3mm & 1mm
Dead time 1.1ms for 1:1 mixing
Drive volume 40 pL per syringe for 1:1 mixing
Dead Volume < 30 pL
Mixing options Single
Detectors (standard) Fluorescence PMT
Operating System Windows XP OS
Table 15: SX 20 Stopped flow instrumentation technical settings held constant for 
stopped- flow kinetic experiments
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>Bs. DHFR
--------------------------------------------------------------- ATGATTTCGC
ACATTCTCCCAATCCATGAAAACCCCCTGATCCCCAAAGACAACCCCTTCCCTTCCCATTTCCCCCCCGA 
TTTGGCGTATTTTAAACGCCTCACAATCCCCCATCCCATCCTCATCCCGCCCAAAACCTTTCAACCCATC 
GGCCCGCCGCTTCCCCGCCGCGATAACGTC GTTGTCACGCCCAACCGCTC CTTTCCCCCCCAAGGC TGCC 
TTGTCCTTCATTCGCTCCAGCAACTCAACCAATGCATCGCATCGCCCCCTCATGAACTGTTTATCATCCC 
CGGGCCCCAACTCTTTCGCGCGACCATCCCCATTCTCCACCCCCTCTATCTCACAAAAATTTTTGCTTCC 
TTCCCCCGCGATACGTTTTATCCGCCCATTTCTGACCATCAATGCCAAATCCTTTCCTATACCCCACCAG 
CCAAACATGAAAAGAATCCCTATGAACACCCCTTTATCATTTATCACCCCAAAAACCCGAAATAC-----
>NC1 . .
CCGGTCACCATTTCCCTCCTTACGAAATAATTTTCTTTAACTTTAACAGCACATATACATATCATTTCGC 
ACATTCTGGCAATGGATGAAAACCGCGTGATCGGCAAAGACAACCGCTTCCCTTGGCATTTCCCGCCCGA 
TTTGGCGTATTTTAAACGGGTGACAATGGGCCATGCCATC GTGATCGGGC CCAAAACCTTTGAAGCCATC 
GGCCGGCCGC TTCCC CGCCGCGATAACCTC GTTGTCACGCCCAAC CGCTC CTTTC CCCCCCAAGGC GCCC 
TTGTCCTTCATTCGCTCGAGCAAGTCAACCAATGGCCCCCATCGCCCCCTCATCAACTCTTTATCATCCG 
CGGGGCCGAACTGTTTCGGGCGACGATGCC GATTGTCGAC CGGCTGTATGTGACAAAAATT TTTGCTTCC 
TTCCCCCCCCATACCTTTTATCCGCCCATTTCTGACGATGAATGCCAAATCGTTTCCTATACCCCACGAG 
GGAAACATGAAAAGAATCCGTATGAACACGCCTTTATCATTTATGAGCGGAAAAACGCGAAATAATGGAT 
CCGAATTCGACCTCCCTCGACAAGCTTCCGCCCCCACTCCAGCACCACCACCACCACCCACTCACATCCG 
CCTGCTAACAAAGCCCCGAAAGCAACCTGACTTTCCCCTGCTGCCCACCCCTCAACCAATAACCTACCCA 
T
Figure 30: C73A/S131C (Bs.DHFR) and I86A (NG1) Nucleic acid sequence.
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p L o b a L  F i t  t h e  p r o g r e s s  o f  WT v s  MTX 0 . 1 s
[ t a s k ]
d a t a  = p r o g r e s s  
t a s k  = f i t
[mechanism]
E + MTX 
EMTX
[constants] 
kl = 67? 
k-1 = 0.01 
k2 = 9 
;k—2 = 0.1?
<===> EMTX : k l  k - 1
E 'MTX : k 2  ; k - 2
u n i t s :  uM, s e c
[ c o n c e n t r a t i o n s ]  ; u n i t s :  uM
E = 1 . 5 ?
EMTX = 0 .0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1?
[ r e s p o n s e s ]  ; p e r c e n t  p r o d u c t / n M  s u b s t r a t e
E = 0 . 6 8 6 ?
MTX = - 0 . 0 2 0 9 ?
EMTX = 0 . 2 3 8 ?
E 'MTX= 0 . 7 9 ?
[ d a t a ]
d i  r e c t o r y  / U s e r s / M a r i  e / D e s k t o p / D a t a / L o w
f i L e  1 0 . 1 s . t x t  | o f f s e t  7 . 4 7 |  c o n c e n t r a t i o n  MTX = 1
d i  r e c t o r y  / U s e r s / M a r i  e / D e s k t o p / D a t a / L o w
f i l e  1 . 5 0 . 0 7 s . t x t  I o f f s e t  7 . 3 7 1 c o n c e n t r a t i o n  MTX = 1 . 5  
d i  r e c t o r y  / U s e r s / M a r  i  e / D e s k t o p / D a t a / L o w  
f i L e  2 0 . 0 6 s . t x t  I o f f s e t  7 . 3 2 1 c o n c e n t r a t i o n  MTX = 2 
d i  r e c t o r y  / U s e r s / M a r  i  e / D e s k t o p / D a t a / L o w  
; f i L e  2 . 5 0 . 1 s . t x t  I c o n c e n t r a t i o n  MTX = 2 . 5  I o f f s e t  6 . 8  
d i  r e c t o r y  / U s e r s / M a r  i  e / D e s k t o p / D a t a / L o w  
f i L e  4 0 . 0 5 s . t x t  I c o n c e n t r a t i o n  MTX =4 | o f f s e t  7 . 2 9  
d i  r e c t o r y  / U s e r s / M a r  i  e / D e s k t o p / D a t a / L o w  
f i L e  5 0 . 0 4 s . t x t  I c o n c e n t r a t i o n  MTX =5 I o f f s e t  7 . 2 6  
d i  r e c t o r y  / U s e r s / M a r  i  e / D e s k t o p / D a t a / L o w  
; f i L e  8 0 . 0 3 s . t x t  I c o n c e n t r a t i o n  MTX =8 I o f f s e t  7 . 4 ?  
d i  r e c t o r y  / U s e r s / M a r  i  e / D e s k t o p / D a t a / L o w  
; f i l e  1 0 0 . 1 s . t x t  | c o n c e n t r a t i o n  MTX = 1 0 | o f f s e t  7 . 4 ?  
[ o u t p u t ]
d i  r e c t o r y  / U s e r s / M a r  i  e / D e s k t o p / o u t p u t / W T . 7 1 5 / 0 . 1
Figure 31: C73A/S131C Script file for DYNAFIT4 fitting of low MTX 
concentrations to give a value for the association rate ki. Similar script was used for 
I86A and Y127A as well as data from PYR binding.
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Global Fit the progress of WT vs PYR 18s
[task]
data = progress 
task = fit
[mechanism]
;E + PYR 
EPYR ---->
[constants]
;kl = 78 
;k-l = 0.81 
k2 = 3?
;k-2 = 0.1?
[concentrations]
;E = 1.5?
EPYR =1.5?
[responses]
;E = 0.686 
;PYR = -0.0209 
EPYR = 0.675?
E'PYR= 0.6?
[data]
d i rectory /Users/Mar i e/Desktop/Data/H i gh
file 2518s.txt | offset 6.14?| ;concentrâtion MTX =25
d i rectory /Users/Mar i e/Desktop/Data/H i gh
;file 5018s.txt I offset 6.28?|;concentrâtion MTX = 50
d i rectory /Users/Mar i e/Desktop/Data/H i gh
file 10010s.txt | offset 6.57?I concentration MTX = 100
[output]
d i rectory /Users/Mar i e/Desktop/output/WT.715/18 
Figure 32: C73A/S131C Script file for DYNAFIT fitting analysis of high PYR 
concentrations to give a value for the conformational change rate k 2. Similar 
script was used for 186A and Y127A as well as data from M T X  binding.
o = = >  EPYR : kl k-1
E'PYR : k2 ;k-2
; units: uM, sec
; units: uM
; percent product/nM substrate
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Global Fit the progress of Y127A vs MTX 608s
[task]
data = progress
task = fit
[mechanism]
EMTX --- > E + MTX : k-1
[constants] 
k-1 =8.81?
; units: uM, sec
[concentrations] 
EMTX= 1?
; units: uM
[responses]
E = 3.4?
MTX = 3.4? 
EMTX = 8.1?
; percent product/nM substrate
[data]
d i rectory /Users/Mar i e/Desktop/Data/358 
file 688s.txt | offset 4.29? 
d i rectory /Users/Mar i e/Desktop/Data/788 
file 788s.txt | offset 4.93?
[output]
d i rectory /Users/Mar i e/Desktop/output/of f rate.15/Y127AMTX.788.358
Figure 33: Y127A Script file for DYNAFIT fitting of competitive experiment data 
with TMP give a value for the dissociation rate k-i. Similar script was used for I86A 
and Y127A as well as data from MTX binding and MDCC labeled enzyme 
dissociation.
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Global Fit the progress of I86AMDCC vs MTX 10s
[task]
data = progress 
task = fit
[mechanism]
E' + MTX ^==> E'MTX : k4 k-4
;E + MTX <===> EMTX : kl k-1
;EMTX --- > E'MTX : k-2
;E--- > E ' : k3
[constants] ; units: uM, sec
;kl = 74 
;k-l =0.02 
k4 = 0.092? 
k-4 = 0.024 
;k—2 = 9?
;k3 = 28?
[concentrations] ; units: uM 
E '= 0.9?
;E = 0.5?
;EMTX = 0.0000001?
[responses] ; percent product/nM substrate
;E = 3.1?
E' = 3.01?
MTX = 0?
E'MTX = 1.95?
;EMTX= 1?
[data]
d i rectory /Users/Mari e/Desktop/Data/10 
;file 1.5.txt | offset 5.92|concentrâtion MTX =1.5 ? 
d i rectory /Users/Mar i e/Desktop/Data/10 
;file 2.5.txtI offset 5.981concentrâtion MTX =2.5 
d i rectory /Users/Mar i e/Desktop/Data/10 
file 5.txt | offset 5.951 concentration MTX =5.84 
d i rectory /Users/Mar i e/Desktop/Data/10 
file 10.txt | offset 5.90|concentrâtion MTX =10.77 
d i rectory /Users/Mar i e/Desktop/Data/10 
file 25.txt I offset 5.8|concentrâtion MTX =26.88 
d i rectory /Users/Mari e/Desktop/Data/10 
file 50.txt I offset 5.751concentrâtion MTX =54.83 
di rectory /Users/Mari e/Desktop/Data/10 
file 100.txt | offset 5.61concentrâtion MTX =93.97 
[output]
d i rectory /Users/Mari e/Desktop/output/186A.2/MTX/10 
Figure 34: I86A mdcc Script file for DYNAFIT fitting of MTX vs MDCC labeled
enzyme to give a value for the association rate k-4. Similar script was used for
C73A/S131Cmdcc and Y127Amdcc as well as data from PYR binding.
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A
■■■HR
B C D E F
A-Ladder 
B-Flow 
through (1) 
C- Row 
through (2) 
D -  Lysate 
E- I86A 
protein 
F-I86Amdcc 
Protein
Figure 35: SDS-PAGE gel of I86A and I86A mdcc proteins, using 4X loading dye 
(lOul Dye and 30ul sample). EZ protein ladder shows the MW sizes and position
A B C D E F
kOa
-1160
-662
- 45.0
- 35.0
-250
- 18.4 
-144
A-Ladder 
B-Y127A 
protein 
C- Lysate 
D -  Flow 
through (1)
E- Wash Last 
F- First Wash
Figure 36: SDS-PAGE gel of Y127A proteins, using 4X loading dye (lOul Dye and 
30ul sample). EZ protein ladder shows the MW sizes and position. Higher band is 
dimer.
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